Pneumococcal vaccination in the elderly: an underused option?
1Department of General Practice and Public Health Science, University of Oulu, Health Centre of Simo-Kuivaniemi, Simo, Finland. Pekka.Honkanen@Oulu.fi
Summary
Pneumococcal infections pose significant risks to the elderly. While the pneumococcal vaccine is effective against bacteremia, its role in preventing pneumonia requires further cost-effectiveness and efficacy evidence for inclusion in national programs.
Area of Science:
- Infectious Diseases
- Vaccinology
- Geriatrics
Background:
- Pneumococcal infections, including pneumonia and bacteremia, are major causes of illness and death in older adults.
- The rise of antibiotic-resistant strains and an aging population highlight the need for effective prevention strategies.
- Existing research on pneumococcal vaccine efficacy for pneumonia prevention in at-risk groups remains inconclusive.
Purpose of the Study:
- To evaluate the effectiveness and rationale of pneumococcal vaccination in preventing pneumococcal infections, particularly pneumonia, in elderly populations.
- To assess the vaccine's impact on pneumococcal bacteremia and consider its clinical utility.
- To analyze the safety profile of the pneumococcal vaccine in the elderly.
Main Methods:
- Review of prospective cohort studies focusing on pneumonia as an endpoint.
- Analysis of data on pneumococcal bacteremia incidence and vaccine effectiveness.
- Assessment of adverse events associated with pneumococcal vaccination.
Main Results:
- Pneumococcal vaccine demonstrates efficacy against pneumococcal bacteremia, though the disease's incidence is relatively low.
- Adverse events from the vaccine are common but generally mild and do not impede use, especially in the elderly.
- Evidence for the vaccine's effectiveness against pneumococcal pneumonia in at-risk groups is still debated.
Conclusions:
- Clinicians should consider pneumococcal vaccination for at-risk elderly patients.
- Further research is needed to confirm the cost-effectiveness and efficacy of pneumococcal vaccine against non-invasive pneumococcal infections before widespread adoption in national programs.
Related Concept Videos
01:30Pneumonia V: Nursing management and Prevention
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:30Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...